Spexib (Ceritinib)

Save 80% over US Zykadia with Spexib by Novarts.

According to the European Medicines Agency, brand name Spexib or Zykadia originating from Europe is manufactured at the following site(s):

Novartis Pharmaceutical Manufacturing LLC Verovškova ulica 57 1000 Ljubljana SloveniaNovartis Pharma GmbH Roonstraße 25 D-90429 Nuremberg GermanyLek farmacevtska družba d.d., Poslovna enota PROIZVODNJA LENDAVA Trimlini 2D 9220 Lendava Slovenia

Information about Spexib (Ceritinib)

Spexib (Ceritinib) is a targeted cancer therapy medication used primarily to treat advanced or metastatic non-small cell lung cancer (NSCLC) that tests positive for anaplastic lymphoma kinase (ALK) gene rearrangements. It is an ALK inhibitor, meaning it blocks the abnormal protein produced by the ALK gene, which is involved in the growth of cancer cells.

Product Highlights

• Spexib is primarily used to treat adults with advanced (metastatic) non-small cell lung cancer (NSCLC) that is ALK-positive and has progressed on or is intolerant to previous treatment with crizotinib, another ALK inhibitor.
• It can also be used as a first-line treatment for ALK-positive NSCLC in patients who have not received previous therapy for their cancer.

Key Ingredient

• Ceritinib

Key Benefits

• Spexib is highly effective in treating ALK-positive metastatic NSCLC and can improve progression-free survival.
• Ceritinib specifically targets the ALK protein, leading to fewer side effects compared to traditional chemotherapy.
• The convenience of taking Spexib orally as opposed to intravenous chemotherapy provides greater ease of use and quality of life for patients.
• For many patients, Spexib helps control disease progression, and can shrink tumors, extending survival.

Direction of Use

• The usual recommended dose of Spexib is 750 mg once daily, taken orally with food. It is essential to adhere to the prescribed dose and avoid exceeding the recommended amount. 
• The capsules should be swallowed whole and must not be chewed, crushed, or opened. 
• The duration of treatment depends on the patient's response to the drug and the progression of their cancer. Ongoing monitoring by a healthcare provider is necessary. 
• If you miss a dose, take it as soon as you remember, unless it's nearly time for your next dose. Do not double the dose.

Safety Concerns

• Common side effects include nausea, diarrhea, and vomiting. These gastrointestinal issues are typically managed with supportive care.
• Ceritinib can cause liver problems, and regular liver function tests are required to monitor for any liver damage.
• Ceritinib can cause a lengthening of the QT interval on an electrocardiogram, which can increase the risk of heart arrhythmias.
• Vision problems, including blurred vision, may occur.
• Myalgia and rhabdomyolysis (muscle breakdown) are rare but serious side effects. If muscle pain or weakness occurs, consult a doctor immediately.
• Ceritinib may interact with other drugs, including those affecting liver enzymes. It is important to inform your healthcare provider about all other medications you are currently taking.

Avoid Spexib (Ceritinib) If

• Do not use Spexib if you are allergic to ceritinib or any of its ingredients. 
• Ceritinib should be avoided in patients with severe liver disease or liver dysfunction. Liver function should be monitored during treatment.
• Ceritinib is not recommended during pregnancy and should be avoided while breastfeeding, as it may harm the unborn child or infant.
• If you have a history of heart problems, particularly arrhythmias or prolonged QT interval, you should avoid using ceritinib unless approved by your healthcare provider.
• Avoid using ceritinib with certain medications that can affect its metabolism, including strong CYP3A inhibitors or inducers.